FARMACIA Y SALUD
Escuela de doctorado
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (9)
2023
-
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294
2022
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry
Digestive and Liver Disease, Vol. 54, Núm. 5, pp. 635-641
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2021
-
Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry
Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42
2019
-
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study
Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500
-
Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients
Clinical and Translational Oncology, Vol. 21, Núm. 4, pp. 467-478
2018
-
Recomendaciones de la Sociedad Española de Farmacia Hospitalaria, la Sociedad Española de Enfermería Oncológica y la Sociedad Española de Oncología Médica para el manejo seguro de la medicación antineoplásica del paciente con cáncer
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 42, Núm. 6, pp. 261-268
2008
-
Methylmalonic acidaemia: Examination of genotype and biochemical data in 32 patients belonging to mut, cblA or cblB complementation group
Journal of Inherited Metabolic Disease, Vol. 31, Núm. 1, pp. 55-66